Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles: Therapeutics, Targets, and Development

Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells

Sean D. McAllister, Rigel T. Christian, Maxx P. Horowitz, Amaia Garcia and Pierre-Yves Desprez
Sean D. McAllister
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rigel T. Christian
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maxx P. Horowitz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amaia Garcia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre-Yves Desprez
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-07-0371 Published November 2007
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    CBD is the most effective inhibitor of invasiveness and Id-1 expression in MDA-MD231 cells. A, the Boyden chamber invasion assay was used to determine the effects of cannabinoids on the invasiveness of aggressive human breast cancer MDA-MB231 cells. Compounds were added at concentrations of 0.1, 1.0, or 1.5 μmol/L. Data are presented as relative invasiveness of the cells through the Matrigel, where the respective controls are set as 100%. B, proteins from MDA-MB231 cells treated with vehicle (control), 0.1, 1.0, or 1.5 μmol/L of CBD for 3 d were extracted and analyzed for Id-1 by Western blot analysis as described in Materials and Methods. C, proteins from MDA-MB231 cells treated with additional cannabinoids for 3 d were extracted and analyzed for Id-1 by Western blot analysis. Normalization was carried out by stripping the blots and reprobing with a monoclonal antitubulin antibody. Densitometry readings of the blots were taken and the percentage of relative expression was calculated as the expression of Id-1 in the treated cells / vehicle cells × 100. D, the inhibitory effect of 1.5 μmol/L of CBD on Id-1 expression was compared over a time course of 1, 2, and 3 d. Columns, mean of at least three replicates; bars, SE. Data were compared using a one-way ANOVA with a corresponding Dunnett's post hoc test. *, P < 0.05, statistically significant differences from control.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    CBD reduces invasion as well as Id-1 expression in MDA-MD436 cells. A, the Boyden chamber invasion assay was used to determine the effects of CBD on the invasiveness of human breast cancer MDA-MB436 cells. Data are presented as relative invasiveness of the cells through the Matrigel, where the respective controls are set as 100%. B, proteins from MDA-MB436 cells treated with vehicle (control) or 2.0 μmol/L of CBD for 3 d were extracted and analyzed for Id-1 by Western blot analysis. Normalization was carried out by stripping the blots and reprobing with a monoclonal antitubulin antibody. C, densitometry readings of the blots were taken from three independent experiments and the percentage of relative expression was calculated as the expression of Id-1 in the treated cells / vehicle cells × 100. *, P < 0.05, statistically significant differences from control.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    CBD inhibits the expression of Id-1 gene at the mRNA and promoter levels in MDA-MB231 and MDA-MB436 cells. A, the inhibition of the Id-1 gene product (434 bp) by CBD was investigated in MDA-MB231 cells using reverse transcription-PCR. Expression of the β-actin gene product (232 bp) was used as a control. B, luciferase activity in MDA-MB231 cells transiently transfected with Id-1-sbsluc was determined in the presence of vehicle (control) or 1.5 μmol/L of CBD. Cells were treated for 2 d and luciferase activity was measured. C, cells were treated for 3 d. For both B and C, all values were normalized for the amount of β-gal activity present in the cell extracts. Columns, mean of at least three replicates; bars, SE. The data are represented as percentage of activity of the treated cells / vehicle cells × 100. Data were compared using the unpaired Student's t test. *, P < 0.05, statistically significant differences from control. D, the inhibition of the Id-1 gene product by CBD was investigated in MDA-MB436 cells using reverse transcription-PCR. Expression of the β-actin gene product was used as a control. E, luciferase activity in MDA-MB436 cells transiently transfected with Id-1-sbsluc was determined in the presence of vehicle (control) or 2 μmol/L of CBD. Cells were treated for 2 d and luciferase activity was measured.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Ectopic expression of Id-1 blocks the effect of CBD on MDA-MB231 invasiveness. A, data are presented as relative invasiveness of control MDA-MB231 cells (−Id-1) and of MDA-MB231 cells that ectopically expressed Id-1 (+Id-1) after a 2-d treatment with vehicle (control) or 1.5 μmol/L of CBD (CBD), and then an overnight invasion assay. The respective controls are set as 100%; columns, mean of at least three replicates; bars, SE. Data were compared using the unpaired Student's t test. *, P < 0.05, statistically significant differences from control. B, the inhibitory effect of CBD on Id-1 expression in −Id-1 and +Id-1 MDA-MB231 cells was compared using Western analysis. Equal loading was confirmed by stripping the blots and reprobing with a monoclonal antitubulin antibody.

Tables

  • Figures
  • Table 1.

    Antiproliferative potencies of cannabinoids during a 3-d treatment of MDA-MB231 and MDA-MB436 breast cancer cells

    CompoundMDA-MB231MDA-MB436
    Embedded ImageΔ9-THC1.2 (1.0–1.4)2.5 (1.8–3.4)
    Embedded ImageCBN1.2 (0.9–1.5)2.6 (1.8–3.7)
    Embedded ImageWIN55,212-21.7 (1.5–2.2)2.4 (1.6–3.4)
    Embedded ImageCP55,9402.5 (1.5–4.1)1.3 (0.7–1.6)
    Embedded ImageCBD1.3 (1.0–1.9)1.6 (1.1–2.2)
    Embedded ImageCBG2.3 (2.1–2.5)2.1 (1.5–3.0)
    • NOTE: Cells were treated with cannabinoid compounds for 3 d and the IC50 values for the antiproliferative effects of the compounds were calculated. Data are the means and corresponding 95% confidence limits of at least three experiments. IC50 values are reported in μmol/L.

PreviousNext
Back to top
Molecular Cancer Therapeutics: 6 (11)
November 2007
Volume 6, Issue 11
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells
Sean D. McAllister, Rigel T. Christian, Maxx P. Horowitz, Amaia Garcia and Pierre-Yves Desprez
Mol Cancer Ther November 1 2007 (6) (11) 2921-2927; DOI: 10.1158/1535-7163.MCT-07-0371

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells
Sean D. McAllister, Rigel T. Christian, Maxx P. Horowitz, Amaia Garcia and Pierre-Yves Desprez
Mol Cancer Ther November 1 2007 (6) (11) 2921-2927; DOI: 10.1158/1535-7163.MCT-07-0371
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Dihydrofolate reductase amplification and sensitization to methotrexate of methotrexate-resistant colon cancer cells
  • MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib
  • Interruption of RNA processing machinery by a small compound, 1-[(4-chlorophenyl)methyl]-1H-indole-3-carboxaldehyde (oncrasin-1)
Show more Research Articles: Therapeutics, Targets, and Development
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement